General Information of Drug (ID: DMVOY6B)

Drug Name
AMD-070 Drug Info
Synonyms
AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
Indication
Disease Entry ICD 11 Status REF
Whim syndrome 4A00.Y Phase 3 [1]
Human immunodeficiency virus infection 1C62 Phase 1/2 [2]
Melanoma 2C30 Phase 1/2 [3]
Merkel cell carcinoma 2C34 Phase 1/2 [3]
Renal cell carcinoma 2C90 Phase 1/2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Cross-matching ID
PubChem CID
11256587
ChEBI ID
CHEBI:138865
CAS Number
CAS 558447-26-0
TTD Drug ID
DMVOY6B

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Plerixafor DMCJN1P Non-hodgkin lymphoma 2B33.5 Approved [5]
Motixafortide DMW34B1 Multiple myeloma 2A83 Approved [6]
Ulocuplumab DM6PMNR Multiple myeloma 2A83 Phase 3 [7]
Balixafortide DMUOFAC Metastatic breast cancer 2C6Y Phase 3 [8]
TG-0054 DM2ZLWH Macular degeneration 9B78.3 Phase 2 [9]
POL-6326 DM4OT29 Human immunodeficiency virus infection 1C62 Phase 2 [10]
CTCE-9908 DM95XR8 Sarcoma 2A60-2C35 Phase 1/2 [11]
USL311 DM6HPEC Recurring respiratory infection CA07-CA45 Phase 1/2 [3]
GMI-1359 DML1KSA Breast cancer 2C60-2C65 Phase 1 [12]
ALX-0651 DMIRYM8 Haematological malignancy 2B33.Y Phase 1 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 4 (CXCR4) TTBID49 CXCR4_HUMAN Antagonist [4]

References

1 ClinicalTrials.gov (NCT03995108) Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8580).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
6 The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
9 CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
10 CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
11 A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
12 Clinical pipeline report, company report or official report of GlycoMimetics.
13 Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.